Stockscreener 앱 받기
6.85
8.73%
0.55
시간 외 거래:
6.85
전일 마감가:
$6.30
열려 있는:
$6.34
하루 거래량:
7.05M
Relative Volume:
2.76
시가총액:
$1.89B
수익:
$248.37M
순이익/손실:
$11.74M
주가수익비율:
-36.05
EPS:
-0.19
순현금흐름:
$18.24M
1주 성능:
+4.74%
1개월 성능:
-0.44%
6개월 성능:
+40.95%
1년 성능:
+105.40%
1일 변동 폭
$6.30
$7.07
1주일 범위
$5.81
$7.07
52주 변동 폭
$3.17
$7.63
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
MNKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
6.85 | 1.89B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
MannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wells Fargo & Company - MarketBeat
MannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 years - Yahoo Finance
MannKind (NASDAQ:MNKD) Trading Up 5.7%Here's Why - MarketBeat
MannKind (NASDAQ:MNKD) Upgraded to Outperform at Royal Bank of Canada - MarketBeat
Tyvaso DPI royalties and pipeline potential boost MannKind stock—RBC - Investing.com
Noteworthy Wednesday Option Activity: MNKD, BTU, FSLR - Nasdaq
MannKind (NASDAQ:MNKD) Shares Gap UpShould You Buy? - MarketBeat
MannKind to issue shares in debt exchange deal - Investing.com
MannKind trims debt with $194 million note exchange - Investing.com
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash - Yahoo Finance
HighTower Advisors LLC Buys 107,560 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
MannKind (NASDAQ:MNKD) Stock Price Down 5.4%Here's Why - MarketBeat
MannKind Becomes Oversold (MNKD) - Nasdaq
Wellington Management Group LLP Acquires 85,977 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) - Barchart
Mannkind Corp (MNKD-Q) QuotePress Release - The Globe and Mail
The Manufacturers Life Insurance Company Grows Stake in MannKind Co. (NASDAQ:MNKD) - Defense World
Cipla’s ‘inhaled insulin’ from US’ MannKind Corp adds a ‘layer of convenience’ for those with diabetes - BusinessLine
CDSCO approves Cipla to distribute, market inhaled insulin in India - Daijiworld.com
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India - Yahoo Finance
Two Sigma Advisers LP Buys 1,000,600 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
MannKind (NASDAQ:MNKD) Cut to "Hold" at StockNews.com - MarketBeat
MannKind Co. (NASDAQ:MNKD) Stock Holdings Increased by BNP Paribas Financial Markets - MarketBeat
MannKind Co. (NASDAQ:MNKD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Jacobs Levy Equity Management Inc. Makes New $12.25 Million Investment in MannKind Co. (NASDAQ:MNKD) - MarketBeat
MannKind Co. (NASDAQ:MNKD) Holdings Lifted by Parkman Healthcare Partners LLC - MarketBeat
MannKind (NASDAQ:MNKD) Upgraded by StockNews.com to Buy Rating - MarketBeat
Insider Sell Alert: Steven Binder Sells 67,536 Shares of MannKin - GuruFocus.com
MannKind director Steven Binder sells $465k in stock By Investing.com - Investing.com Nigeria
MannKind director Steven Binder sells $465k in stock - Investing.com India
MannKind (NASDAQ:MNKD) Downgraded to Hold Rating by StockNews.com - Defense World
Principal Financial Group Inc. Purchases 134,937 Shares of MannKind Co. (NASDAQ:MNKD) - Defense World
MannKind Co. (NASDAQ:MNKD) Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
MannKind (STU:NNFN) Inventories, Raw Materials & Components : €5.8 Mil (As of Sep. 2024) - GuruFocus.com
MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN
MannKind Corp director Steven Binder sells $456,563 in stock - Investing.com India
MannKind Corp director Steven Binder sells $456,563 in stock By Investing.com - Investing.com Nigeria
Insulin Pump Market Report 2024-2035, Featuring Profiles of Leading Players Including Beta Bionics, CeQur, EOFlow, Insulet, LA Roche, MannKind, Medtronic, Medtrum Technologies and MicroPort - Yahoo Finance
MannKind Corporation (NASDAQ:MNKD) Q3 2024 Earnings Call Transcript - Insider Monkey
MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 5 - GuruFocus.com
MannKind Corp's chief people officer Stuart Tross sells $403,700 in stock - Investing.com Australia
Earnings call: MannKind sees growth and pipeline progress in Q3 2024 - Investing.com
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Quantisnow
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Re - GuruFocus.com
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
MannKind (MNKD) Q3 2024 Earnings Call Transcript - Yahoo! Voices
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
MannKind Corp Q3 2024 Earnings: EPS of $0.04 Beats Estimates, Re - GuruFocus.com
MannKind (MNKD) Matches Q3 Earnings Estimates - Yahoo Finance
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
맨카인드 주식 (MNKD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Binder Steven B. | Director |
Nov 22 '24 |
Sale |
6.89 |
67,536 |
465,323 |
1,075,026 |
2.88%
2.65%
자본화:
|
볼륨(24시간):